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Abstract Melatonin is known as a strong antioxidant and
possesses anti-inflammatory properties. Recently, melatonin
was shown to improve colitis in animal models of inflamma-
tory bowel diseases. The aim of the present study was to
characterize the role of melatonin receptors (MT) in the anti-
inflammatory effect of melatonin and to assess the anti-
inflammatory potential of two novel MT receptor agonists,
Neu-P11 and Neu-P67, in the mouse mode l o f
trinitrobenzenesulfonic acid (TNBS)-induced colitis. Colitis
was induced on day 1 by intracolonic (i.c.) administration of
TNBS in 30 % ethanol in saline. Melatonin (4 mg/kg, per os
(p.o.)), Neu-P11 (20 mg/kg, p.o.; 50 mg/kg, intraperitoneally
(i.p.), 50 mg/kg, i.c.), and Neu-P67 (20 mg/kg, p.o.) were
given twice daily for 3 days. Luzindole (5 mg/kg, i.p.) was
injected 15 min prior to melatonin administration. On day 4,
macroscopic and microscopic damage scores were assessed
and myeloperoxidase (MPO) activity quantified using O-
dianisidine-based assay. Melatonin significantly attenuated
colitis in mice, as indicated by the macroscopic score
(1.90 ± 0.34 vs. 3.82 ± 0.62 for melatonin- and TNBS-
treated mice, respectively), ulcer score (0.87 ± 0.18 vs.
1.31 ± 0.19, respectively), and MPO activity (4.68 ± 0.70
vs.6.26 ± 0.94, respectively). Luzindole, a MT receptor antag-
onist, did not inhibit the anti-inflammatory effect of melatonin
(macroscopic score 1.12 ± 0.22, ulcer score 0.50 ± 0.16); how-
ever, luzindole increased MPO activity (7.57 ± 1.05). MT
receptor agonists Neu-P11 and Neu-P67 did not improve in-
flammation induced by TNBS. Melatonin, but not MT recep-
tor agonists, exerts potent anti-inflammatory action in acute
TNBS-induced colitis. Our data suggests that melatonin atten-
uates colitis by additional, MT receptor-independent
pathways.
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Introduction
Melatonin is a hormone produced from tryptophan mainly by
the pineal gland, but also in peripheral organs, including im-
mune cells and the gastrointestinal (GI) tract (Chen et al.,
2011), where it is secreted by enterochromaffin cells of the
GI mucosa. The concentration of melatonin in the GI tract is
approximately 400 higher than in the pineal gland. Melatonin
exerts multiple activities, including antioxidative, immuno-
modulatory, and anti-inflammatory (Bubenik, 2008).
Consequently, melatonin has been regarded as a strong anti-
oxidant and scavenger of peroxynitrite, peroxyl, oxygen, and
superoxide anion radicals.
The primary mechanism of melatonin action is stimulation
of melatonin receptors (MT), which belong to the G protein-
coupled receptor family (Pandi-Perumal et al., 2008). In mam-
mals, two types of MT receptors have been identified: Mel1a
and Mel1b, later renamed MT1 and MT2. MT receptor activa-
tion leads to inhibition of adenylyl cyclase activity and causes
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decrease in cAMP concentration. In addition, MT2 receptor-
dependent signaling also involves cGMP-related pathways.
In the GI tract, MT receptors were found in the mu-
cosa, submucosa, muscle cells, and myenteric plexus.
The highest expression of MT receptors was detected in
the small intestine, duodenum, and colon (Poirel et al.,
2003). In humans, MT2 receptors are widely distributed
in epithelial and endocrine cells as well as submucosal
and myenteric plexuses of the large intestine. In the
small intestine, the MT2 expression in the submucosal
and myenteric plexuses and in the epithelial cells is
strong in comparison with MT1 receptors. Moreover,
MT1 receptors are not located on the vascular and endo-
crine cells of the small intestine (Soderquist et al., 2015).
MT receptors have also been located on the membrane of
immune cells (e.g., CD4 T, CD8 T, and B lymphocytes)
(Garcia-Maurino et al., 2000a; Lardone et al., 2010), and mel-
atonin was found to regulate both cellular and humoral re-
sponse via MT receptors (Drazen and Nelson, 2001).
Through MT receptors, melatonin regulates the activation of
transcriptional factors involved in immunological responses
as well as immune cell differentiation and proliferation
(Morgan et al., 1995). It has also been reported that the pro-
liferation of T cells increases in mice treated with melatonin
(Lin et al., 2013).
Lately, it was proposed that the impairment in the re-
lease and distribution of endogenous melatonin may be
involved in the pathogenesis of inflammatory bowel dis-
eases (IBD): Crohn’s disease and ulcerative colitis
(Cuzzocrea et al., 2001b; Mauriz et al., 2013). In line, it
was evidenced that melatonin improves colitis in numer-
ous animal models of IBD (Chung et al., 2014; Jena and
Trivedi, 2014; Tasdemir et al., 2013; Trivedi and Jena,
2013). For example, melatonin attenuated colitis induced
by intracolonic instillation of dinitrobenzenesulfonic acid
(DNBS) in rats (Cuzzocrea et al., 2001a). The anti-
inflammatory effect was observed in an improved colonic
architecture and decreased infiltration of immune cells;
the myeloperoxidase (MPO) level was also significantly
decreased. Moreover, melatonin inhibited oxidative stress,
as indicated by a reduced level of malonyl dialdehyde
(MDA) and prevented the upregulation of adhesion mol-
ecules, ICAM-1 and P-selectin, in the colon. Finally, al-
leviation of COX-2 and iNOS expression was observed.
In another study, melatonin prevented lipid peroxidation
in DNBS-induced colitis, assessed by thiobarbituric acid
reactive substances (TBARS) levels, confirming its anti-
oxidative activity (Esposito et al., 2008). Melatonin also
reduced colonic inflammatory injury through downregula-
tion of pro-inflammatory molecules, e.g., TNF-α, in a
NF-κB-dependent manner (Li et al., 2005), inhibition of
c-Jun, phosphorylation, and MMP-2 and MMP-9 activity
and expression (Esposito et al., 2008).
Noteworthy, in most of the published studies, melatonin
exerted an antioxidative effect and improved microcirculation
in the intestinal epithelium (Reiter et al., 2003).
Recently, two novel MT receptor agonists, Neu-P11 and
Neu-P67, were developed (She et al., 2009). Both compounds
display high affinity at MT receptors and prolonged duration
of action. In addition, Neu-P11 has potent antinociceptive ef-
fect after per os (p.o.) administration (Chen et al., 2011) and
significantly inhibits GI motility (unpublished results). The
aim of this study was to compare the possible anti-
inflammatory effect of Neu-P11 and Neu-P67 with melatonin
and to characterize the involvement of MT receptors in the
course of the intestinal inflammation in the mouse model of
trinitrobenzenesulfonic acid (TNBS)-induced colitis.
Materials and methods
Animals
Male balb/c mice (Animal Facility of Nofer Institute of
Occupational Medicine, Lodz, Poland), weighing 24–26 g,
were used in the experiments. Mice were housed at a constant
temperature (22–23 °C) and maintained under a 12-h light/
dark cycle with the access to laboratory chow and tap water.
The study was carried out in strict accordance with the
institutional recommendations. The protocol was approved
by the Local Ethical Committee for Animal Experiments (#
589/2011).
Drugs
Melatonin and luzindole were purchased from Tocris
Bioscience (Ellisville, MO, USA). Neu-P11 and Neu-P67
were obtained from Neurim Pharmaceuticals Ltd., Israel. All
other reagents, unless otherwise stated, were purchased from
Sigma-Aldrich (Poznan, Poland).
Pharmacological treatments
Melatonin, Neu-P11, Neu-P67, and luzindole were dissolved
in 5% dimethyl sulfoxide (DMSO) in saline. Animals without
treatment received vehicle alone (5 % DMSO in saline).
Melatonin was administered p.o. at the dose of 4 mg/kg;
Neu-P11 was given p.o. (20 mg/kg), i.p. (50 mg/kg), or i.c.,
50 mg/kg; and Neu-P67 was administered p.o. (20 mg/kg).
Luzindole was administered i.p. at the dose of 5 mg/kg 15min
prior to melatonin injection. The first treatment with the drug
(melatonin, Neu-P11, NeuP-67, luzindole) was 15 min before
the induction of colitis with TNBS.
All drugs were given twice daily from day 1–day 3 and
prepared before injections. The doses of all drugs used in
our experiments were selected based on our preliminary
512 Naunyn-Schmiedeberg's Arch Pharmacol (2016) 389:511–519
studies and available literature (Chen et al., 2011; Trivedi and
Jena, 2013).
Induction of colitis and assessment of colonic damage
Colitis was induced by i.c. injection of trinitrobenzenesulfonic
acid (TNBS) on day 1, as described previously (Sobczak et al.,
2014b). Briefly, mice (n = 6–8 per group) were anesthetized
with isoflurane (Aerrane, Baxter, Deerfield, USA) and TNBS
(4mg in 0.1 ml of 30% ethanol in saline) was injected into the
distal colon (2.5 cm proximally to the anus) using a catheter.
Mice were weighted daily and monitored for clinical symp-
toms of colitis, including diarrhea and bloody stool. On day 4,
animals were sacrificed and the total macroscopic score was
assessed. The total macroscopic score is a sum of the follow-
ing parameters: for ulcer score 0.5 points for each 0.5 cm,
adhesion (0–2), wall thickness measured in millimeters, pres-
ence of hemorrhage; fecal blood and diarrhea increased the
score by 1 point for each additional feature.
Moreover, samples for assessment of MPO activity and for
histology were collected and kept in −80 °C and 4 °C,
respectively.
Determination of tissue myeloperoxidase activity
To monitor the degree of inflammation, isolated colon sec-
tions (15–30 mg) were washed and homogenized in
hexadecyltrimethylammonium bromide (HTAB) buffer
(0.5 % HTAB in 50 mM potassium phosphate buffer, pH
6.0; 50 mg of tissue/ml) using Ika Ultra Turrax Disperser
T25 Digital 2 (Sigma-Aldrich, Poznan, Poland).
Homogenates were centrifuged (15 min, 13.200×g, 4 °C),
and the supernatants were collected to new tubes. Next, 7 μl
of supernatant was added on a 96-well plate, followed by
200 μl of 50 mM potassium phosphate buffer (pH 6.0), con-
taining 0.167 mg/ml of O-dianisidine hydrochloride and
0.05 μl of 1 % hydrogen peroxide. Absorbance was measured
at 450 nm after 30 and 60 s (iMARK Microplate Reader,
Biorad, UK). MPO activity was expressed in milliunits per
gram of wet tissue, as described earlier (Sobczak et al.,
2014a). MPO assay is a sensitive test and therefore to obtain
representative results, all measurements were performed in
triplicate for 6–8 colon sections collected from all animals in
the group.
Histology
Distal colon sections were stapled flat, mucosal side-up, onto
cardboard strips and fixed in 4 % formalin for >24 h at 4 °C.
Samples were dehydrated, embedded in paraffin, sectioned at
5 μm, and mounted onto slides. Sections were stained with
hematoxylin and eosin and examined using a microscope
(Motic AE31, Ted Pella, Sweden). Photographs were taken
using a digital imaging system consisting of a digital camera
(Moticam 2300, Ted Pella, Sweden) and image analysis soft-
ware (Motic Images Plus 2.0, Germany).
The microscopic total damage score was assessed as de-
scribed previously (Galeazzi et al., 1999, with minor modifi-
cations), using the following parameters: the extent of muscle
thickening, and the presence and degree of immune cell infil-
tration (normal = 1, moderate = 2, transmural = 3), the de-
struction of mucosal architecture (normal = 1, moderate = 2,
extensive = 3), and the goblet cell depletion and crypt abscess-
es (presence = 1, absence = 0).
Statistical analysis
The results are expressed as mean ± standard error of the
mean (SEM). Values given with Bn^ refer to the number
of experiments performed in tissues from different ani-
mals. Statistical analysis was performed using Prism 5.0
(GraphPad Software Inc., La Jolla, CA, USA). ANOVA
followed by Newman-Keuls post hoc testing was used for
multiple comparisons. p values <0.05 were considered sta-
tistically significant.
Results and discussion
In the present study, we confirmed that melatonin exerts
a potent anti-inflammatory action in the mouse model of
TNBS-induced colitis. In contrast, Neu-P11, a multi-
targeted drug candidate with combined functionality at
MT1\MT2 receptors (sleep promoting, neuroprotection)
and 5HT1A\D receptors (antidepressant and anxiolytic
effects), did not exert anti-inflammatory action in the
GI tract. Similarly, Neu-P67, a potent agonist of MT1/
MT2 receptors and an inhibitor of fatty acid amide hy-
drolase (FAAH), an enzyme involved in degradation of
endocannabinoids, also failed to attenuate colonic
inflammation.
As shown in Fig. 1, melatonin given p.o. at the dose of
4 mg/kg twice daily significantly improved colitis in mice,
as indicated by the macroscopic score (1.90 ± 0.34 vs.
3.82 ± 0.62 for TNBS-treated mice) and ulcer score
(0.87 ± 0.18 vs. 1.31 ± 0.19). Noteworthy, administration of
melatonin decreased MPO activity (4.67 ± 0.70 vs.
6.26 ± 0.94). In the colon, tissue injury progression occurs
because of leukocyte infiltration and release of free oxygen
radicals from activated immune cells, which further induce
pro-inflammatory cytokine production. MPO expressed in
the immune cells, in the presence of Cl− converts hydrogen
peroxide to hypochloric acid (HOCl), which is a potent oxi-
dant and antimicrobial agent, and plays important role in im-
mune response. Since MPO activity in the colon is linearly
Naunyn-Schmiedeberg's Arch Pharmacol (2016) 389:511–519 513
related to the infiltration of immune cells, it is well established
for quantification of colitis.
Body weight is another important parameter in the devel-
opment of colitis. In this study, loss of weight was observed in
animals after TNBS instillation, but not in the control group.
Furthermore, a less significant loss of body weight and a
quicker recovery was noted in mice treated with melatonin
(data not shown). Our results are consistent with data obtained
by Cuzzocrea et al. (Cuzzocrea et al., 2001a), who evidenced
that the anti-inflammatory effect of melatonin was observed
through an improved colonic architecture, decreased infiltra-
tion of immune cells, and significantly lower MPO level.
Consequently, we hypothesized that Neu-P11, which dis-
plays high binding affinity at MT receptors and has good oral
bioavailability, should also improve colitis. However, we ob-
served that Neu-P11 did not attenuate colitis in mice after p.o.
administration at the dose of 20 mg/kg (twice daily), as shown
by the macroscopic score (3.76 ± 0.72 vs. 3.88 ± 0.08 for
TNBS-treated mice), MPO activity (21.35 ± 9.54 vs.
21.62 ± 4.26), and the ulcer score (0.43 ± 0.43 vs.
1.00 ± 0.01, p = 0.24; Fig. 2). To further investigate its effect
in the inflamed colon, Neu-P11 was injected i.p. and i.c. (both
50 mg/kg, twice daily). We observed no anti-inflammatory
action of Neu-P11 administered i.p. (macroscopic score
4.28 ± 0.27 vs. 5.07 ± 0.29, MPO activity 12.72 ± 0.96 vs.
17.57 ± 2.75, ulcer score 2.08 ± 0.27 vs. 2.25 ± 0.14 for Neu-
P11 vs. TNBS-treated mice, respectively; Fig. 3) or i.c. (mac-
roscopic score 4.28 ± 0.27 vs. 5.07 ± 0.29, p = 0.08, MPO
activity 19.19 ± 2.27 vs. 16.69 ± 5.42, ulcer score 2.08 ± 0.27
vs. 2.25 ± 0.14 for Neu-P11 vs. TNBS-treated mice, p = 0.65,
respectively; Fig. 4).
Earlier reports showed that the inhibition of FAAH signif-
icantly attenuated inflammation in several animal models of
colitis (Salaga et al., 2014), what encouraged us to use Neu-
P67, a novel mixed MT receptor agonist—FAAH blocker in
this study. However, Neu-P67 did not alleviate colitis in mice
after p.o. administration (macroscopic score 3.92 ± 1.10 vs.
3.88 ± 0.08, ulcer score 0.83 ± 0.40 vs. 1.00 ± 0.00 for Neu-
P67 and TNBS-treated mice, respectively; Fig. 5a–b).
Surprisingly, Neu-P67 significantly decreased MPO activity
(5.85 ± 2.40 vs. 21.62 ± 4.26 for TNBS and Neu-P67 vs.
TNBS alone-treated mice, respectively, p = 0.008; Fig. 5C).
This observation was not in line with macro- and microscopic
analysis, but remained consistent throughout replicates. It sug-
gests that Neu-P67 affects the immune cell infiltration; more-
over, possibly non-MT receptor-dependent mechanisms, e.g.,
involving inhibition of FAAH, are very likely to play a role in
the decrease ofMPO activity observed in this study. However,
further examination is required to understand this process.
The macroscopic scoring was consistent with microscopic
imaging. As shown in Fig. 6, the architecture of the colon in
TNBS-treated mice was disrupted; the tissue was infiltrated
with immune cells, the muscle layer was thicker, and the mu-
cosal layer severely damaged compared with control. The
microscopic parameters were improved after melatonin
(4 mg/kg, p.o., twice daily; Fig. 6C), but not Neu-P11
(20 mg/kg, p.o.; Fig. 6D; 50 mg/kg i.p.; Fig. 6E; 50 mg/kg
i.c.; Fig. 6F) or Neu-P67 (20 mg/kg, p.o., twice daily; Fig. 6G)
treatment.
Because we did not observe any anti-inflammatory activity
of novel MT receptor agonists Neu-P11 and Neu-P67, we
Fig. 1 Oral administration of melatonin at the dose of 4 mg/kg twice
daily significantly attenuated colitis in mice but blockage ofMT receptors
did not cause worsening of the intestinal inflammation. Figure shows data
for macroscopic score (a), MPO activity (b), ulcer score (c), and colon
length (d). ***p < 0.001 as compared with control, ##p < 0.01,
###p < 0.001 as compared with TNBS-treated animals, @@@ as com-
pared with melatonin-treated mice. Data represent mean ± SEM, n = 6–8
mice per group
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decided to verify the role of MT receptors in the anti-
inflammatory effect of melatonin. We thus used luzindole, a
competitive MT receptor antagonist (Dubocovich et al.,
1998). Surprisingly, luzindole did not block the action of mel-
atonin, as indicated by macroscopic and ulcer score
Fig. 3 Intraperitoneal injection of Neu-P11 at the dose of 50 mg/kg twice
daily did not improve colitis inmice. Figure shows data formacroscopic score
(a), MPO activity (b), ulcer score (c), and colon length (d). **p < 0.01,
***p < 0.001 as compared with control. Data represent mean ± SEM,
n = 6–8 mice per group
Fig. 2 Oral administration of Neu-P11 at the dose of 20 mg/kg twice
daily did not improve colitis in mice. Figure shows data for macroscopic
score (a), MPO activity (b), ulcer score (c), and colon length (d).
*p < 0.05, ***p < 0.001 as compared with control. Data represent
mean ± SEM, n = 6–8 mice per group
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(1.90 ± 0.34 and 0.87 ± 0.18 for melatonin-treated group vs.
1.17 ± 0.22 and 0.50 ± 0.16 for melatonin + luzindole-treated
Fig. 4 Intracolonic injection of Neu-P11 at the dose of 50 mg/kg twice
daily did not improve colitis in mice. Figure shows data for macroscopic
score (a), MPO activity (b), ulcer score (c), and colon length (d).
**p < 0.01, ***p < 0.001 as compared with control. Data represent
mean ± SEM, n = 6–8 mice per group
Fig. 5 Oral administration of Neu-P67 at the dose of 20 mg/kg twice daily
did not improve macroscopic score, but decreased MPO activity in TNBS-
treated mice. Figure shows data for macroscopic score (a), MPO activity (b),
ulcer score (c), and colon length (d). **p < 0.01, ***p < 0.001 as compared
with control, ##p < 0.01, as compared with TNBS-treated animals. Data
represent mean ± SEM, n = 6–8 mice per group
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group), Fig 1. Luzindole did not improve MPO activity
(4.68 ± 0.70 for melatonin-treated group vs. 7.57 ± 1.05 for
melatonin + luzindole-treated group) and microscopic damage
score (5.40 ± 0.51 for melatonin-treated group vs. 7.75 ± 0.70 for
melatonin + luzindole-treated group). Of note, luzindole slightly
improved macroscopic scoring in mice, what suggests that mel-
atonin has a great anti-inflammatory potential even when MT
receptors are blocked. Interestingly, luzindole increased MPO
level, suggesting that modulation of leukocyte recruitment could
be partially mediated byMT2 receptors (luzindole exerts 15–25-
fold higher selectivity for MT2 than MT1 receptors). However,
development of highly selective MT1 and MT2 antagonists
would help to better understand the role of MT receptors in
physiological and pathophysiological processes.
Collectively, our data suggests that the activation of MT re-
ceptors, which is sufficient to produce antinociception and potent
inhibition of GI motility, does not produce anti-inflammatory
effect in the colon. Consequently, pathways other than MT
receptor-dependent may be involved in the anti-inflammatory
action of melatonin. This is in line with a study by Lahiri et al.
(Lahiri et al., 2009), in which melatonin at the doses ranging
from 10 to 40mg/kg injected i.p. exerted protective role in reflux
esophagitis. Melatonin-induced effect on antioxidant parameters
(MDA, SOD, and GSH) and expression of pro-inflammatory
molecules, including TNF-α, IL-1β, and IL-6 levels in the
colon, was not reversed by luzindole. These results sug-
gest a MT receptor-independent action, what is consis-
tent with our observations (Lahiri et al., 2009).
Fig. 6 Melatonin attenuated microscopic damage score. Microscopic
total damage score and representative micrographs of hematoxylin and
eosin-stained sections of distal colon from a control, b TNBS, c TNBS
and melatonin (4 mg/kg, p.o., twice daily), d TNBS andmelatonin (4 mg/
kg, p.o., twice daily) co-administered with luzindole (5 mg/kg, i.p.), e
TNBS and Neu-P11 (20 mg/kg, p.o., twice daily), f TNBS and Neu-P11
(50 mg/kg, i.p., twice daily), g TNBS and Neu-P11 (50 mg/kg, i.c., twice
daily) treated mice, (H) TNBS and Neu-P67 (20 mg/kg, p.o., twice daily),
and i total microscopic damage score. Scale bar = 100 μm. ***p < 0.001,
as compared with control. #p < 0.05, ###p < 0.001, as compared with
TNBS-treated mice. @@p < 0.01, as compared with melatonin-treated
mice. Data represent mean ± SEM, n = 6–8 mice per group
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Despite a number of additional experiments, we did not
manage to identify the non-MT receptor-related mechanism
of action of melatonin. Earlier studies suggest that melatonin
can bind with nuclear binding receptors, namely retinoid or-
phan receptors/retinoid Z receptors (ROR/RZR), located on
lymphocytes and monocytes (Garcia-Maurino et al., 2000b).
Through this pathway, melatonin is involved in the reg-
ulation of immunological processes and influences lym-
phocyte T maturation (Smirnov, 2001). Moreover, mel-
atonin was a potent inhibitor of the expression of 5-
lipoxygenase in human B cells, an important enzyme
involved in allergy and inflammation also through
ROR/RZR (Missbach et al., 1996).
Furthermore, melatonin binds to calmodulin and
calreticulin, involved in the cytoskeleton regulation and con-
trol of nuclear receptors (Pedrosa et al., 2010). Calmodulin
and calreticulin inhibit protein activation, followed by protein
distribution and cell cycle disruption (Blask et al., 2002).
Another possible binding site for melatonin is quinone reduc-
tase 2, which participates in the protection against oxidative
stress by preventing electron transfer reactions of quinones
(Nosjean et al., 2000).
Kang et al. showed that melatonin attenuated the increased
expression of TLR at protein level after ischemia and reperfu-
sion injury (Kang et al., 2011). Moreover, melatonin de-
creased TNF-α, IL-6, and iNOS levels, but also triggered
MAPK and NF-κB. The inhibitory action of melatonin may
be thus combined with MyD88 signaling of the TLR system
(Kang et al., 2011).
The antioxidative properties of melatonin could also play a
role in its anti-inflammatory effect (Zhang and Zhang, 2014).
Namely, melatonin activates antioxidative enzymes, e.g., su-
peroxide dismutase, catalase and glutathione peroxidase, glu-
tathione reductase (GSH-Rd), and glucose-6-phosphate dehy-
drogenase (G6PD). Moreover, melatonin inhibits the expres-
sion of inducible nitric oxide syntase (iNOS). Eventually, mel-
atonin directly influences hydroxyl radical, hydrogen peroxide,
nitric oxide, and singlet oxygen secretion (Dziegiel et al., 2003).
Finally, the anti-inflammatory potential of melatonin may
be associated with the action of its metabolites (Galano et al.,
2013). MT agonists, Neu-P11, and Neu-P67 are not metabo-
lized to the same products as melatonin. Melatonin can be
processed in the liver to 6-hydroxymelatonin and further to
6-hydroxymelatonin glucuronide or 6-sulphomelatonin; an al-
ternate metabolic pathway includes formation of N1-acetyl-
N2-formyl-5-metoxy-kynuramine (AMFK) or more stable
N1-acetyl-5-metoxy-kynuramine (AMK), which share
the antioxidative and anti-inflammatory properties with
the substrate (Konturek et al., 2007). Interestingly,
AMFK and AMK are more potent antioxidants than
melatonin against nitric oxide (Galano et al., 2013),
and AMK possesses the highest antioxidative activity
of all three (Ressmeyer et al., 2003).
Conclusions
Taken together, our data indicate that the anti-inflammatory
effect of melatonin in the colon is independent of MT recep-
tors. Based on earlier reports, we suggest that the most
likely mechanism of action may be associated with an-
tioxidant properties of melatonin. In addition, since we
observed no aggravation of TNBS-induced colitis upon
treatment with novel MT receptor agonists Neu-P11 and
Neu-P67, they may be safely used in other (e.g., func-
tional) GI diseases as well as to promote sleep and as
antidepressant and anxiolytic agents.
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